Ticagrelor Tablet, Film Coated
Product Images NDC 62332-500

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 62332-500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 10 (Ticagrelor 10figure)

A line graph comparing the cumulative percentage of events over 360 days from randomization for Ticagrelor 90 mg and Clopidogrel. The graph includes data on the number of patients at risk over time and a summary box with event counts, Kaplan-Meier percentages at 12 months, hazard ratio with confidence interval, and p-value.*

FDA Label Image

Figure 11 (Ticagrelor 11figure)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus Clopidogrel across various patient and treatment characteristics. The chart includes subgroups by geographic region, ASA dose, planned treatment approach, early PCI, CABG patients, diabetes history, prior TIA/stroke, glycoprotein IIb/IIIa inhibitor use, age group, sex, and race, displaying relative efficacy between Ticagrelor and Clopidogrel.*

FDA Label Image

Figure 12 (Ticagrelor 12figure)

A data table comparing the hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across different aspirin dose levels (<=100 mg, >100 to <300 mg, >=300 mg) and regions (US and Non-US). The table includes sample sizes (N) and events (E) for each group, alongside a forest plot illustrating the HR with markers indicating whether Ticagrelor or Clopidogrel is favored.*

FDA Label Image

Figure 13 (Ticagrelor 13figure)

A line graph showing cumulative percentage versus days from randomization for ticagrelor 60 mg, 90 mg, and placebo. The graph includes Kaplan-Meier survival estimates comparing ticagrelor doses with placebo over approximately 1,300 days, with statistical data on patients, events, hazard ratio, confidence intervals, and p-values displayed in a legend.*

FDA Label Image

Figure 14 (Ticagrelor 14figure)

A forest plot chart presenting hazard ratios (HRs) with 95% confidence intervals (CI) comparing Ticagrelor versus placebo across various patient subgroups and characteristics, including age, sex, race, weight, BMI, geographic region, medical history, and treatment details. The chart visually assesses treatment effects by subgroup using HR scales indicating 'Ticagrelor Better' and 'Placebo Better.'*

FDA Label Image

Figure 15 (Ticagrelor 15figure)

A Kaplan-Meier cumulative percentage curve showing events over months from randomization for Ticagrelor versus Placebo. The solid line represents Ticagrelor and the dashed line Placebo, with cumulative event percentages on the y-axis and months on the x-axis up to 54 months. Patient numbers at risk are listed below the chart for both groups.*

FDA Label Image

Figure 16 (Ticagrelor 16figure)

A forest plot showing hazard ratios with 95% confidence intervals comparing Ticagrelor versus placebo in various patient subgroups. The plot includes characteristics like age, sex, race, body mass index, geographic region, baseline aspirin dose, HbA1c, renal function, insulin use, history of angina, coronary artery disease, PCI, CABG, smoking status, and diabetes duration. The x-axis ranges from 0.5 (Ticagrelor better) to 2 (Placebo better).*

FDA Label Image

Figure 17 (Ticagrelor 17figur)

A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg twice daily (bd) and placebo over approximately 34 days from randomization. The y-axis shows cumulative percentage events, while the x-axis shows days. The Ticagrelor group displays a lower cumulative event percentage than placebo. The number at risk is shown below for each group at various time points.*

FDA Label Image

Figure 18 (Ticagrelor 18figur)

A forest plot chart depicting hazard ratios (HR) with 95% confidence intervals comparing Ticagrelor and placebo across various patient subgroups characterized by age, sex, race, weight, BMI, geographic region, diagnosis, timing of treatment, diabetes, hypertension, prior medical conditions, and smoking status. The plot visualizes summary statistics for Ticagrelor versus placebo effectiveness and safety in these categories.*

FDA Label Image

Figure 1 (Ticagrelor 1figure)

A cumulative percentage graph comparing Ticagrelor 90 mg and Clopidogrel over 360 days from the first study drug dose. The y-axis represents cumulative percentage, increasing to about 4.5%, and the x-axis shows days. Population at risk data points are listed below the graph for both drugs. Ticagrelor shows a slightly higher cumulative percentage than Clopidogrel throughout the period.*

FDA Label Image

Figure 2 (Ticagrelor 2figure)

A bar chart showing the percentage of patients who had an event following CABG surgery over various days (1 to >=8). The chart compares two groups labeled T and C for each day, with percentages displayed on the vertical axis and days on the horizontal axis. Numeric values are listed below each group for context.*

FDA Label Image

Figure 3 (Ticagrelor 3figure)

A line graph showing cumulative percentage over months from randomization comparing Ticagrelor (solid line) and placebo (dashed line). The Y-axis represents cumulative percentage (%) up to 7%, and the X-axis shows time in months up to 54. Patient counts at risk are listed beneath the graph for both Ticagrelor and placebo groups at multiple time points.*

FDA Label Image

Figure 4 (Ticagrelor 4figure)

A cumulative percentage plot showing the comparison between Ticagrelor 90 mg twice daily and placebo over 34 days from randomization. The graph tracks cumulative events percentage, with Ticagrelor represented by a solid line and placebo by a dashed line, including risk numbers at various intervals.*

FDA Label Image

Figure 5 (Ticagrelor 5figure)

A line graph depicting IPA (%) induced by 20uM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The y-axis shows IPA (%) while the x-axis shows time from 0 to 8 hours. Ticagrelor shows a rapid and high increase in IPA, Clopidogrel a moderate increase, and placebo minimal change over time, with error bars included.*

FDA Label Image

Figure 6 (Ticagrelor 6figure)

A line graph showing IPA (%) induced by 20 μM ADP over time in days, comparing Ticagrelor, Clopidogrel, and Placebo treatments. Ticagrelor shows the highest IPA initially, followed by Clopidogrel, with Placebo showing minimal effect. An inset graph shows IPA (%) over 48 hours on a finer time scale.*

FDA Label Image

Figure 7 (Ticagrelor 7figure)

A chart showing mean effect and 90% confidence intervals of Ticagrelor and AR-C124910XX across intrinsic factors including age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and mild hepatic impairment. The x-axis represents change relative to reference, with PK parameters Cmax and AUC displayed as squares and triangles, respectively. Recommendations state no dose adjustment for all factors.*

FDA Label Image

Figure 8 (Ticagrelor 8fig)

A chart illustrating the mean effect and 90% confidence interval for Ticagrelor with various interacting drugs, showing their impact on pharmacokinetic parameters (PK, Cmax, AUC) and corresponding dosing recommendations, such as avoiding concomitant use or no dose adjustment needed.*

FDA Label Image

Figure 9 (Ticagrelor Figure 9)

A pharmacokinetic chart showing the mean effect and 90% confidence intervals of ticagrelor doses on various interacting drugs (simvastatin, atorvastatin, levonorgestrel, ethinyl estradiol, tolbutamide, digoxin, ciclosporin). The graph depicts changes relative to interacting drug alone, with a recommendation column advising dose adjustments or no dose adjustment for each drug.*

FDA Label Image

Structure (Ticagrelor Structure)

Chemical structure of the active ingredient Ticagrelor, showing its molecular arrangement and specific atomic bonds typical for this compound.*

FDA Label Image

30 Tablets (Ticagrelor Tabs 90 mg)

Label for Ticagrelor Tablets 90 mg film-coated oral tablets by Alembic Pharmaceuticals Inc. The label shows a package of 30 tablets with NDC 62332-241-30. It includes dosage instructions, warnings, storage information, manufacturer details for Alembic Pharmaceuticals Limited in India and Alembic Pharmaceuticals, Inc. in the USA, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.